tweetindex
RU

Circulation Research

@CircRes · joined 12 Oct 2009

Circulation Research is an AHA journal focusing on basic science & translational cardiovascular research. https://t.co/DbXiggw5ZE https://t.co/ElAzkCBwac

30 117Followers
48Following
7 633Posts total
5.8KViews on collected posts

Последние посты

The study by Roy et al reveals how the immune system contributes to #atherosclerosis. These findings may enable new antigen-specific approaches for treatment of #CVD. Learn more at https://t.co/uo71VLyjiJ @ImmunologyAU @MCG_AU @IrLeBar https://t.co/W0YfGDA7R6 939 views · 10 likes · 2 reposts · 0 replies Open on X →
@CircRes The CXCL13 result raises a key question: does disrupting TLS formation preserve protection while limiting rupture risk, or does it broadly dampen beneficial immune surveillance? I’m digging into this with Sci-Quest, a platform for biomedical literature reviews: 13 views · 0 likes · 0 reposts · 0 replies Open on X →
The study by Zheng et al reveals that tertiary lymphoid structures form in brain #aneurysm walls & are associated with rupture. Blocking #CXCL13 signaling pathway reduced aneurysm formation & rupture in a mouse model. Learn more at https://t.co/5IbIuEkSA4 https://t.co/lerm5OGClj 1.2K views · 8 likes · 1 reposts · 1 replies Open on X →
@CircRes The soluble-vs-membrane TREM2 distinction seems key here—do we know whether HSP90β targeting changes shedding, downstream signaling, or both? I’m digging into it with Sci-Quest, a biomedical literature review platform: https://t.co/AMUYFvZ8PU 14 views · 0 likes · 0 reposts · 0 replies Open on X →
Guo & colleagues found that plasma soluble #TREM2 promotes pro-atherogenic #myeloid recruitment & inflammatory #macrophage activation. Learn more about targeting #HSP90β for therapy at https://t.co/jzk67TzkRN https://t.co/ca91ry2BPe 1.4K views · 11 likes · 7 reposts · 1 replies Open on X →
Thürmann et al found in teenagers diastolic high #BP was linked to a distinct #inflammatory protein pattern in urine, which may signal early changes related to future #CV or #kidney disease. Learn more at https://t.co/Al6h4Lj1Oi https://t.co/miI0zNBZDc 1.1K views · 1 likes · 0 reposts · 0 replies Open on X →
ICYMI: the latest episode of #DiscoverCircRes is out! https://t.co/tVRVcTrM1m @StHilaireLab chats with Drs. @jonathankirk, Laura A. Sherer, and @abbynagle about their study "Contractility Drives Cardiomyocyte Maturation and the Response to Nanopatterns" https://t.co/JzqQAcvVPJ h 1.1K views · 4 likes · 4 reposts · 1 replies Open on X →

На фоне аккаунтов своего размера

7 постов за последние 90 дней рядом с диапазоном 10K–100K подписчиков. обычный охват для своего размера, отклик слабее, чем у большинства.

Медианные просмотры1 119этот аккаунт924медиана для 10K–100K
Охват, %3.72%этот аккаунт3.62%медиана для 10K–100K
Вовлечённость, %0.80%этот аккаунт1.52%медиана для 10K–100K
ПоказательЭтот аккаунтМедиана для 10K–100KОтношение
Медианные просмотры на пост1 1199241.21×
Охват (просмотры ÷ подписчики)3.72%3.62%1.03×
Вовлечённость0.80%1.52%0.53×

Другие в этом диапазоне →   Сравнить с другим аккаунтом →   Как считаются эти ориентиры →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

1.1K30 Aug
1.1K31 Aug
1.4K2 Sep
143 Sep
1.2K4 Sep
13
9396 Sep

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.80%30 Aug
0.09%31 Aug
1.35%2 Sep
0.00%3 Sep
0.85%4 Sep
0.00%
1.28%6 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes59.6%34 in total
Reposts24.6%14 in total
Replies5.3%3 in total
Bookmarks10.5%6 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Похожие аккаунты